Sunshine Biopharma Inc. (SBFM) - 10-K Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Sunshine Biopharma Inc. for the fiscal year ended December 31, 2025. The Company is a pharmaceutical entity operating primarily in Canada through its subsidiary, Nora Pharma Inc., which markets 71 generic prescription drugs. Additionally, the Company develops proprietary drug candidates, including K1.1 mRNA (oncology) and SBFM-PL4 (antiviral), both currently in animal testing stages. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $36,305,891 | $34,874,283 |
| Cost of Sales | $24,050,214 | $24,204,489 |
| Gross Profit | $12,255,677 | $10,669,794 |
| Gross Margin | 33.8% | 30.6% |
| Net Loss | $(5,975,352) | $(5,134,116) |
| Accumulated Deficit | $(75,015,126) | $(69,039,774) |
| Cash and Equivalents | $9,123,308 | $9,686,529 |
| Operating Cash Flow | $(5,331,073) | $(12,524,779) |
| Inventory | $13,472,025 | $11,278,105 |
Debt and Liquidity: The Company has no notes payable. Total liabilities were $7,040,707 as of December 31, 2025, primarily consisting of accounts payable and lease liabilities. Management believes existing cash reserves are sufficient to fund operations for the next 18 months.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by approximately $1.4 million (4.1%) driven by expanded sales efforts in Quebec, Ontario, Alberta, and British Columbia.
- Cost Efficiency: Cost of sales decreased by 3.2% despite revenue growth, attributed to lower professional allowances outside Quebec and reduced wholesaler fees.
- Impairment Charge: General and Administrative (G&A) expenses increased by $2.0 million, primarily due to a non-cash impairment charge of $1,748,247 related to intangible assets (product licenses deemed uncommercializable).
- Net Loss Expansion: Net loss increased by $841,236 year-over-year, largely due to the impairment charge and reduced interest income.
- Capital Structure: The Company issued 1,188,404 shares in a registered direct offering in April 2025 and exercised warrants for additional shares, raising net proceeds of approximately $4.7 million in financing activities.
Guidance, Outlook, and Risks
Outlook and Initiatives: Management implemented cost-reduction initiatives in January 2026, targeting a $2 million to $3 million reduction in G&A expenses for 2026. The Company plans to launch 12 additional generic drugs in the remainder of 2026. Proprietary drug candidates (K1.1 and SBFM-PL4) remain in preclinical animal testing stages with no FDA filings made to date.
Risks and Contingencies:
- Profitability: The Company has an accumulated deficit of $75 million and may never achieve profitability.
- Supply Chain: Approximately 75% of the generic drug portfolio is manufactured by three overseas suppliers, creating concentration risk.
- Regulatory: Generic drug pricing in Canada is heavily dependent on government reimbursement frameworks (pCPA), which pose pricing pressure risks.
- Legal Proceedings:
- Mr. Malek Chamoun: Following his termination in April 2025, the former President of Nora Pharma demanded approximately $5.3 million USD. The Company disputes this claim and has made no accrual.
- Mr. Andrew Telsey: A former legal counsel demanded $3.6 million. The Company filed a complaint, and on March 30, 2026, the court entered a default judgment in the Company's favor, declaring the alleged agreement void.
- Stock Listing: The Company trades on Nasdaq Capital Market. While currently compliant, stock prices have traded near the $1.00 minimum bid price requirement, posing a potential delisting risk if not maintained.
Investor Verification Checklist
- Intangible Asset Impairment: Verify the specific product licenses written off ($1.75M) and the rationale for deeming them uncommercializable.
- Legal Exposure: Monitor the status of the dispute with Mr. Malek Chamoun regarding the $5.3 million demand and potential impact on future cash flows.
- Supplier Concentration: Assess the risk mitigation strategies regarding the three suppliers that manufacture 75% of the generic portfolio.
- Cost Reduction Plan: Track the execution of the $2M-$3M G&A expense reduction plan for 2026.
- Nasdaq Compliance: Monitor the stock price relative to the $1.00 minimum bid price requirement to assess delisting risk.
- Proprietary Pipeline: Confirm the timeline for transitioning K1.1 mRNA and SBFM-PL4 from animal testing to human clinical trials (IND filing).